Status:
RECRUITING
Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients
Lead Sponsor:
Fundación EPIC
Conditions:
Ischemic Heart Disease
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
This registry will provide exploratory and descriptive information regarding contemporary practice patterns of parenteral antiplatelet therapy in the PCI (Percutaneous Coronary Intervention) setting a...
Detailed Description
The present study is an observational, multicenter, nationwide, prospective investigation in patients undergoing PCI due to any coronary syndrome (acute or chronic) and receiving parenteral antiplatel...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Undergoing a PCI
- Use of a parenteral antiplatelet agent (GPIs or cangrelor)during the invasive procedure (PCI)
Exclusion
- Blood dyscrasia, bleeding diathesis or active bleeding at the time of the index procedure.
- Chronic oral anticoagulation.
- Recent history of stroke, TIA (Transient Ischemic Attack)or intracranial bleeding (\<3 months prior to inclusion).
- Severe anemia (Hb\<9g/dl) or platelet count \<100x106/ml at the time of the index procedure.
- Any active neoplasm.
Key Trial Info
Start Date :
March 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05193019
Start Date
March 14 2022
End Date
December 1 2025
Last Update
January 15 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain, 08907
2
Hospital Universitario de Cruces
Barakaldo, Spain, 48903
3
Hospital de Galdakao
Galdakao, Spain, 48960
4
Hospital Universitario de Cabueñes
Gijón, Spain, 33394